<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00615836</url>
  </required_header>
  <id_info>
    <org_study_id>FE992026 CS31</org_study_id>
    <nct_id>NCT00615836</nct_id>
  </id_info>
  <brief_title>An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving (&quot;Melt&quot;) Formulation of Desmopressin for the Treatment of Nocturia in Adults</brief_title>
  <official_title>A Multi-Center Extension Study Investigating the Long Term Efficacy and Safety of a Fast-Dissolving (&quot;Melt&quot;) Formulation of Desmopressin for the Treatment of Nocturia in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to investigate the long term efficacy and safety of several
      doses of the Melt formulation of desmopressin in a broad population of adult patients with
      nocturia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FE992026 CS31 was a multicenter open-label extension study for patients who were enrolled in
      Study FE992026 CS29 (NCT00477490) and had completed at least Visit 3E in Part II of that
      study.

      The CS29 study was structured into 2 double-blind parts (Part I and Part II). In Part I, the
      initial 28-day treatment period, participants were randomly assigned to 1 of 5 treatment
      groups: placebo or desmopressin Melt 10 μg, 25 μg, 50 μg, or 100 μg. Immediately upon
      completion of Part I of the study, all participants on active treatment continued into Part
      II on the same treatment for approximately 1 to 6 months. Participants assigned to placebo in
      Part I were randomly assigned to 1 of the 4 active treatments in Part II, based on
      re-randomization predetermined at the initial randomization (to maintain the blind). Part II
      began at the final visit for Part I and continued until the database for Part I was locked.
      Therefore, treatment duration for Part II varied between 1 and 6 months, depending upon when
      the participant entered.

      Upon completion of Part II of CS29, participants were given the option to participate in the
      open-label extension study (CS31). During CS31, each participant assigned to the 10 μg dose
      was switched to a higher dose in an open-label manner among the remaining 3 higher doses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Number of Nocturnal Voids</measure>
    <time_frame>Baseline of Study CS29 and Weeks 8, 12, 20, 28, 52-56, 72-76, and 92-96.</time_frame>
    <description>Participants completed a voiding diary for 3 consecutive 24-hour periods prior to the study visit in which they recorded each nocturnal urination (void). The mean number of voids per night was the average number of voids from the 3-day diary. Baseline refers to Baseline of Study CS29 and the number of weeks represents the total exposure to study drug.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Greater Than 33% Reduction in the Mean Number of Nocturnal Voids</measure>
    <time_frame>Baseline of Study CS29 and Weeks 8, 12, 20, 28, 52-56, 72-76, and 92-96.</time_frame>
    <description>Percentage of participants with &gt;33% reduction from Baseline in the mean number of nocturnal urinations per night, calculated from the 3-day voiding diary completed prior to each study visit.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Initial Period of Undisturbed Sleep</measure>
    <time_frame>Baseline of Study CS29 and Weeks 8, 12, 20, 28, 52-56, 72-76, and 92-96.</time_frame>
    <description>Participants completed a sleep diary on 3 consecutive mornings prior to each study visit, from which the initial period of undisturbed sleep was calculated and averaged for the 3 days. The Initial Period of Undisturbed Sleep is the time elapsed from bedtime to either first void or morning arising minus the minutes it took to fall asleep. Baseline refers to Baseline of Study CS29 and the number of weeks represents the total exposure to study drug.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Sleep Time</measure>
    <time_frame>Baseline of Study CS29 and Weeks 8, 12, 20, 28, 52-56, 72-76, and 92-96.</time_frame>
    <description>Participants completed a sleep diary on 3 consecutive mornings prior to each study visit, from which the total sleep time was calculated and averaged for the 3 days. Baseline refers to Baseline of Study CS29 and the number of weeks represents the total exposure to study drug.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in International Consultation on Incontinence Modular Questionnaire - Nocturia (ICIQ-N) Nighttime Urination Bother Score</measure>
    <time_frame>Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)</time_frame>
    <description>The ICIQ-N is a self-administered 4-item questionnaire designed to assess the frequency and bother of daytime and nighttime urination. To assess nighttime urination bother, participants were asked to rate the degree of bother of nighttime urination by answering the question &quot;Night time urination: How much does this bother you?&quot; on a scale ranging from 0 (not at all) to 10 (a great deal). Higher numbers indicate greater bother.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nocturia Quality of Life (NQoL) Overall Score</measure>
    <time_frame>Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)</time_frame>
    <description>The NQoL is a self-administered 13-item questionnaire designed to assess the impact of nocturia on quality of life. It contains a sleep/energy domain (6 questions), a bother/concern domain (6 questions), and 1 global QoL question (which is not included in the overall score). The 12 core items are scored on a 0 to 4 scale, and the overall score is calculated by transforming the raw score into a 0-100 scale with higher numbers indicating better impact on quality of life.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in NQoL Bother/Concern Domain Score</measure>
    <time_frame>Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)</time_frame>
    <description>The NQoL is a self-administered 13-item questionnaire designed to assess the impact of nocturia on quality of life. It contains a sleep/energy domain (6 questions), a bother/concern domain (6 questions), and 1 global QoL question. The 12 core items are scored on a 0 to 4 scale with higher numbers indicating a better quality of life. The bother/concern domain summary score is calculated by transforming the raw score into a 0-100 scale with higher numbers indicating a better impact on quality of life.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nocturia Quality of Life (NQoL) Sleep/Energy Domain Score</measure>
    <time_frame>Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)</time_frame>
    <description>The NQoL is a self-administered 13-item questionnaire designed to assess the impact of nocturia on quality of life. It contains a sleep/energy domain (6 questions), a bother/concern domain (6 questions), and 1 global QoL question. The 12 core items are scored on a 0 to 4 scale with higher numbers indicating a better quality of life. The sleep/energy domain summary score is calculated by transforming the raw score into a 0-100 scale with higher numbers indicating a better impact on quality of life.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Nocturia Quality of Life (NQoL) Global Quality of Life Score</measure>
    <time_frame>Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)</time_frame>
    <description>The NQoL is a self-administered 13-item questionnaire designed to assess the impact of nocturia on quality of life. It contains a sleep/energy domain (6 questions), a bother/concern domain (6 questions), and 1 global QoL question. The global QoL question is scored on a scale ranging from 0 (not at all) to 10 (a great deal). Higher numbers indicate better impact on quality of life.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Global Score</measure>
    <time_frame>Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)</time_frame>
    <description>The PSQI is a self-administered 19-item questionnaire designed to assess sleep quality and disturbances. The 19 individual items are scored on an evenly weighted 0 to 3 scale and generate 7 component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these 7 components yields 1 global score ranging from 0 to 21. Higher numbers indicate greater sleep disturbance.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Short Form-12, Version 2 (SF-12v2) Mental Component Summary Score</measure>
    <time_frame>Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)</time_frame>
    <description>The SF-12v2 was used to measure the impact of nocturia and lack of sleep on general quality of life. The SF-12 consists of 12 questions spanning 8 domains: physical functioning, role function-physical, role function-emotional, bodily pain, general health, vitality, social functioning, and mental health. These scales are combined to create 2 summary measures: the Physical Health Summary and Mental Health Summary. The Mental Health Summary score ranges from 0 to 100, where higher numbers indicate better quality of life.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Short Form-12, Version 2 (SF-12v2) Physical Component Summary Score</measure>
    <time_frame>Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)</time_frame>
    <description>The SF-12v2 was used to measure the impact of nocturia and lack of sleep on general quality of life. The SF-12 consists of 12 questions spanning 8 domains: physical functioning, role function-physical, role function-emotional, bodily pain, general health, vitality, social functioning, and mental health. These scales are combined to create 2 summary measures: the Physical Health Summary and Mental Health Summary. The Physical Health Summary score ranges from 0 to 100, where higher numbers indicate better quality of life.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Treatment-Emergent Adverse Events (AEs)</measure>
    <time_frame>From first dose of study drug in Study CS29 until the end of study CS31 (up to 35 months).</time_frame>
    <description>An AE was any untoward medical occurrence that did not necessarily have a causal relationship with the study drug. An adverse drug reaction (ADR) was an AE evaluated by the Investigator as being probably or possibly causally related to treatment with the study drug.
A serious AE (SAE) was any event that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or congenital anomaly/birth defect or was an important medical event that could have jeopardized the patient's safety or required medical or surgical intervention to prevent 1 of the outcomes listed above. The intensity of an AE was defined as severe if it resulted in the inability to work or perform usual activities.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">554</enrollment>
  <condition>Nocturia</condition>
  <arm_group>
    <arm_group_label>Desmopressin Melt 10 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received desmopressin melt 10 μg once a day, placed under the tongue one hour before bedtime until they were re-randomized to one of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desmopressin Melt 25 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received desmopressin melt 25 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desmopressin Melt 50 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received desmopressin melt 50 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desmopressin Melt 100 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received desmopressin melt 100 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desmopressin Melt</intervention_name>
    <description>An orally disintegrating tablet of desmopressin administered under the tongue (sublingually), without water.</description>
    <arm_group_label>Desmopressin Melt 10 μg</arm_group_label>
    <arm_group_label>Desmopressin Melt 25 μg</arm_group_label>
    <arm_group_label>Desmopressin Melt 50 μg</arm_group_label>
    <arm_group_label>Desmopressin Melt 100 μg</arm_group_label>
    <other_name>Minirin® Melt</other_name>
    <other_name>Nocturin®</other_name>
    <other_name>FE992026</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent prior to the performance of any study-related activity.

          -  Was randomized into Part II of Protocol FE992026 CS29 (NCT00477490), entitled &quot;A
             Randomized, Double Blind,Placebo Controlled, Parallel Group, Multi-Center Study with a
             Double Blind Extension Investigating the Efficacy and Safety of a Fast-Dissolving
             (&quot;Melt&quot;) Formulation of Desmopressin for the Treatment of Nocturia in Adults&quot; and have
             completed at least Visit 3E in Part II (Day 15).

        Exclusion Criteria:

          -  Patients using loop diuretics (furosemide, torsemide, ethacrynic acid).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Primary Care Clinic, PA</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Urology Medical Center</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Impact Clinical Trials</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Professional Research</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Uro-Reseach</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Clinical Research</name>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <zip>91356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Clinical Research</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates PC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downtown Women's Health Care</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genitourinary Surgical Consultants</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Clinical Research Center, LLC</name>
      <address>
        <city>Middlebury</city>
        <state>Connecticut</state>
        <zip>06762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Research Group, LLC</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - St. Petersburg</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Medical Research</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34996</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Urology</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Kansas City</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureCare Studies, Inc.</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Minneapolis</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Clinic of Lincoln, P.C.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheldon J Freedman Ltd</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Jersey Medical Research Center</name>
      <address>
        <city>Elizabeth</city>
        <state>New Jersey</state>
        <zip>07202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrenceville Urology, P.A. DBA</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Group of New Mexico, PC</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site - Adult &amp; Pediatric Urology</name>
      <address>
        <city>Carmel</city>
        <state>New York</state>
        <zip>10512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Urology Associates</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Urology</name>
      <address>
        <city>NY</city>
        <state>New York</state>
        <zip>12206-1092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudson Valley Urology, PC</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmQuest</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hanover Medical Research</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Medical Research Associates</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Akron</name>
      <address>
        <city>Mogadore</city>
        <state>Ohio</state>
        <zip>44260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologic Consultants of SE PA</name>
      <address>
        <city>Bala Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia Clinical Research, LLC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Concepts</name>
      <address>
        <city>West Readings</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Greer</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Medical Research</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Associates</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site - NationsMed Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Medical Center and Diagnostic</name>
      <address>
        <city>Humble</city>
        <state>Texas</state>
        <zip>77338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMED Research, P.A.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NationsMed</name>
      <address>
        <city>Stafford</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Urology</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia PC</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Clinical Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Urology Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Interior Medical Research Inc.</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y-2H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Can-Med Clinical Research Inc.</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 5G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site - Clinical Research</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site - Professional Corporation</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <zip>E3B 5B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Male/Female Health and Research</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brantford Urology Research</name>
      <address>
        <city>Brantford</city>
        <state>Ontario</state>
        <zip>N3R 4N3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guelph Urology Associates</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <zip>N1H 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 7K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fe/Male Health Centres</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6H 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2008</study_first_submitted>
  <study_first_submitted_qc>February 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2008</study_first_posted>
  <results_first_submitted>June 23, 2015</results_first_submitted>
  <results_first_submitted_qc>November 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 15, 2015</results_first_posted>
  <disposition_first_submitted>October 4, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>October 4, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 5, 2010</disposition_first_posted>
  <last_update_submitted>November 11, 2015</last_update_submitted>
  <last_update_submitted_qc>November 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nocturia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was open only to participants who were enrolled in Study FE992026 CS29 (NCT00477490) and had completed at least Visit 3E in Part II (Day 15) of that study. 799 patients were randomized to treatment in CS29, and 601 patients formed the intent-to-treat population in CS29. This population was used to assess durability of effect in CS31.</recruitment_details>
      <pre_assignment_details>Participants were initially assigned in a blinded manner to the same treatment dose received in Study CS29. After CS29 database lock, CS31 was unblinded, and based on the results of CS29, participants assigned to 10 μg were randomly assigned at their next scheduled visit to 25 μg, 50 μg, or 100 μg of desmopressin Melt.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Desmopressin Melt 10 μg</title>
          <description>Participants received desmopressin Melt 10 μg once a day, placed under the tongue 1 hour before bedtime for between 2-7 months in Study CS29, continuing in Study CS31.
During CS31, based on the results of CS29, participants were randomly assigned to 1 of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).</description>
        </group>
        <group group_id="P2">
          <title>Desmopressin Melt 25 μg</title>
          <description>Participants received desmopressin Melt 25 μg once a day, placed under the tongue 1 hour before bedtime for between 2-7 months in Study CS29 and for up to 2 years and 2.5 months in Study CS31.</description>
        </group>
        <group group_id="P3">
          <title>Desmopressin Melt 50 μg</title>
          <description>Participants received desmopressin Melt 50 μg once a day, placed under the tongue 1 hour before bedtime for between 2-7 months in Study CS29 and for up to 2 years and 2.5 months in Study CS31.</description>
        </group>
        <group group_id="P4">
          <title>Desmopressin Melt 100 μg</title>
          <description>Participants received desmopressin Melt 100 μg once a day, placed under the tongue 1 hour before bedtime for between 2-7 months in Study CS29 and for up to 2 years and 2.5 months in Study CS31.</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Participants took a placebo 'Melt' for 28 days to complete Part I of Study CS29. In Part II, placebo patients were randomized to 1 of the other 4 treatment arms to receive active desmopressin Melt, continuing into Study CS31.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part I of Core Study (FE992026 CS29)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="158"/>
                <participants group_id="P3" count="158"/>
                <participants group_id="P4" count="160"/>
                <participants group_id="P5" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-treat Population</title>
              <participants_list>
                <participants group_id="P1" count="155">Received at least 1 dose of study drug and provided at least 1 primary efficacy measure.</participants>
                <participants group_id="P2" count="152">Received at least 1 dose of study drug and provided at least 1 primary efficacy measure.</participants>
                <participants group_id="P3" count="148">Received at least 1 dose of study drug and provided at least 1 primary efficacy measure.</participants>
                <participants group_id="P4" count="146">Received at least 1 dose of study drug and provided at least 1 primary efficacy measure.</participants>
                <participants group_id="P5" count="156">Received at least 1 dose of study drug and provided at least 1 primary efficacy measure.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="148"/>
                <participants group_id="P3" count="138"/>
                <participants group_id="P4" count="135"/>
                <participants group_id="P5" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Extension Study (FE992026 CS31)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="144"/>
                <participants group_id="P3" count="132"/>
                <participants group_id="P4" count="137"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="59"/>
                <participants group_id="P4" count="53"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="86"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="84"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serum sodium ≤125 mmol/L</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Use of exclusionary medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="43"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not reported</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Re-randomized to a higher dose</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Demographic data provided for the Efficacy Analysis Dataset, which consisted of the intent-to-treat population from CS29 (all randomized patients who received at least 1 dose of study drug and provided at least 1 primary efficacy measure during Part I) who were on active treatment (i.e., placebo participants are not included).</population>
      <group_list>
        <group group_id="B1">
          <title>Desmopressin Melt 10 μg</title>
          <description>Participants received desmopressin Melt 10 μg once a day, placed under the tongue 1 hour before bedtime until they were re-randomized to 1 of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).</description>
        </group>
        <group group_id="B2">
          <title>Desmopressin Melt 25 μg</title>
          <description>Participants received desmopressin Melt 25 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
        </group>
        <group group_id="B3">
          <title>Desmopressin Melt 50 μg</title>
          <description>Participants received desmopressin Melt 50 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
        </group>
        <group group_id="B4">
          <title>Desmopressin Melt 100 μg</title>
          <description>Participants received desmopressin Melt 100 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="155"/>
            <count group_id="B2" value="152"/>
            <count group_id="B3" value="148"/>
            <count group_id="B4" value="146"/>
            <count group_id="B5" value="601"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.7" spread="14.41"/>
                    <measurement group_id="B2" value="62.4" spread="13.22"/>
                    <measurement group_id="B3" value="61.6" spread="11.80"/>
                    <measurement group_id="B4" value="62.1" spread="12.34"/>
                    <measurement group_id="B5" value="61.9" spread="12.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="80"/>
                    <measurement group_id="B5" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="80"/>
                    <measurement group_id="B5" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="119"/>
                    <measurement group_id="B4" value="111"/>
                    <measurement group_id="B5" value="473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian/Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian/other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnic Origin</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="135"/>
                    <measurement group_id="B4" value="140"/>
                    <measurement group_id="B5" value="562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Number of Nocturnal Voids</title>
        <description>Participants completed a voiding diary for 3 consecutive 24-hour periods prior to the study visit in which they recorded each nocturnal urination (void). The mean number of voids per night was the average number of voids from the 3-day diary. Baseline refers to Baseline of Study CS29 and the number of weeks represents the total exposure to study drug.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
        <time_frame>Baseline of Study CS29 and Weeks 8, 12, 20, 28, 52-56, 72-76, and 92-96.</time_frame>
        <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants received desmopressin Melt 10 μg once a day, placed under the tongue 1 hour before bedtime until they were re-randomized to 1 of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants received desmopressin Melt 25 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants received desmopressin Melt 50 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants received desmopressin Melt 100 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Number of Nocturnal Voids</title>
          <description>Participants completed a voiding diary for 3 consecutive 24-hour periods prior to the study visit in which they recorded each nocturnal urination (void). The mean number of voids per night was the average number of voids from the 3-day diary. Baseline refers to Baseline of Study CS29 and the number of weeks represents the total exposure to study drug.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
          <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
          <units>nocturnal voids</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8 Weeks [N=103, 96, 92, 104]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.12" spread="1.166"/>
                    <measurement group_id="O2" value="-1.30" spread="1.180"/>
                    <measurement group_id="O3" value="-1.42" spread="1.278"/>
                    <measurement group_id="O4" value="-1.47" spread="1.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks [N=85, 81, 77, 81]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" spread="1.151"/>
                    <measurement group_id="O2" value="-1.40" spread="1.249"/>
                    <measurement group_id="O3" value="-1.48" spread="1.155"/>
                    <measurement group_id="O4" value="-1.73" spread="1.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 Weeks [N=62, 58, 64, 64]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="1.167"/>
                    <measurement group_id="O2" value="-1.61" spread="1.175"/>
                    <measurement group_id="O3" value="-1.69" spread="1.167"/>
                    <measurement group_id="O4" value="-1.86" spread="1.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Weeks [N=63, 85, 62, 62]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="1.389"/>
                    <measurement group_id="O2" value="-1.36" spread="1.141"/>
                    <measurement group_id="O3" value="-1.49" spread="1.276"/>
                    <measurement group_id="O4" value="-1.81" spread="0.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52-56 Weeks [N=45, 91, 81, 77]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.79" spread="1.291"/>
                    <measurement group_id="O2" value="-1.40" spread="1.224"/>
                    <measurement group_id="O3" value="-1.78" spread="1.342"/>
                    <measurement group_id="O4" value="-2.14" spread="1.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72-76 Weeks [N=0, 79, 72, 67]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants remained in this treatment group.</measurement>
                    <measurement group_id="O2" value="-1.51" spread="1.253"/>
                    <measurement group_id="O3" value="-1.86" spread="1.345"/>
                    <measurement group_id="O4" value="-2.24" spread="1.287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>92-96 Weeks [N=0, 68, 62, 62]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants remained in this treatment group.</measurement>
                    <measurement group_id="O2" value="-1.39" spread="1.180"/>
                    <measurement group_id="O3" value="-1.91" spread="1.359"/>
                    <measurement group_id="O4" value="-2.09" spread="1.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Greater Than 33% Reduction in the Mean Number of Nocturnal Voids</title>
        <description>Percentage of participants with &gt;33% reduction from Baseline in the mean number of nocturnal urinations per night, calculated from the 3-day voiding diary completed prior to each study visit.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
        <time_frame>Baseline of Study CS29 and Weeks 8, 12, 20, 28, 52-56, 72-76, and 92-96.</time_frame>
        <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants received desmopressin Melt 10 μg once a day, placed under the tongue 1 hour before bedtime until they were re-randomized to 1 of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants received desmopressin Melt 25 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants received desmopressin Melt 50 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants received desmopressin Melt 100 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Greater Than 33% Reduction in the Mean Number of Nocturnal Voids</title>
          <description>Percentage of participants with &gt;33% reduction from Baseline in the mean number of nocturnal urinations per night, calculated from the 3-day voiding diary completed prior to each study visit.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
          <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8 Weeks [N=103, 96, 92, 104]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3"/>
                    <measurement group_id="O2" value="63.5"/>
                    <measurement group_id="O3" value="67.4"/>
                    <measurement group_id="O4" value="68.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks [N=85, 81, 77, 81]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="67.9"/>
                    <measurement group_id="O3" value="70.1"/>
                    <measurement group_id="O4" value="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 Weeks [N=62, 58, 64, 64]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5"/>
                    <measurement group_id="O2" value="79.3"/>
                    <measurement group_id="O3" value="76.6"/>
                    <measurement group_id="O4" value="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Weeks [N=63, 85, 62, 62]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.5"/>
                    <measurement group_id="O2" value="65.9"/>
                    <measurement group_id="O3" value="74.2"/>
                    <measurement group_id="O4" value="87.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52-56 Weeks [N=45, 91, 81, 77]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.6"/>
                    <measurement group_id="O2" value="73.6"/>
                    <measurement group_id="O3" value="71.6"/>
                    <measurement group_id="O4" value="88.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72-76 Weeks [N=0, 79, 72, 67]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants remained in this treatment group.</measurement>
                    <measurement group_id="O2" value="69.6"/>
                    <measurement group_id="O3" value="77.8"/>
                    <measurement group_id="O4" value="86.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>92-96 Weeks [N=0, 68, 62, 62]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants remained in this treatment group.</measurement>
                    <measurement group_id="O2" value="63.2"/>
                    <measurement group_id="O3" value="77.4"/>
                    <measurement group_id="O4" value="88.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Initial Period of Undisturbed Sleep</title>
        <description>Participants completed a sleep diary on 3 consecutive mornings prior to each study visit, from which the initial period of undisturbed sleep was calculated and averaged for the 3 days. The Initial Period of Undisturbed Sleep is the time elapsed from bedtime to either first void or morning arising minus the minutes it took to fall asleep. Baseline refers to Baseline of Study CS29 and the number of weeks represents the total exposure to study drug.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
        <time_frame>Baseline of Study CS29 and Weeks 8, 12, 20, 28, 52-56, 72-76, and 92-96.</time_frame>
        <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants received desmopressin Melt 10 μg once a day, placed under the tongue 1 hour before bedtime until they were re-randomized to 1 of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants received desmopressin Melt 25 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants received desmopressin Melt 50 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants received desmopressin Melt 100 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Initial Period of Undisturbed Sleep</title>
          <description>Participants completed a sleep diary on 3 consecutive mornings prior to each study visit, from which the initial period of undisturbed sleep was calculated and averaged for the 3 days. The Initial Period of Undisturbed Sleep is the time elapsed from bedtime to either first void or morning arising minus the minutes it took to fall asleep. Baseline refers to Baseline of Study CS29 and the number of weeks represents the total exposure to study drug.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
          <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8 Weeks [N=93, 82, 83, 90]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.64" spread="118.822"/>
                    <measurement group_id="O2" value="96.58" spread="112.750"/>
                    <measurement group_id="O3" value="104.72" spread="120.236"/>
                    <measurement group_id="O4" value="126.63" spread="114.501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks [N=78, 69, 66, 72]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.57" spread="116.855"/>
                    <measurement group_id="O2" value="116.70" spread="110.738"/>
                    <measurement group_id="O3" value="118.71" spread="112.450"/>
                    <measurement group_id="O4" value="144.77" spread="116.376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 Weeks [N=55, 51, 59, 58]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.51" spread="113.892"/>
                    <measurement group_id="O2" value="115.60" spread="105.136"/>
                    <measurement group_id="O3" value="133.66" spread="151.510"/>
                    <measurement group_id="O4" value="155.44" spread="119.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Weeks [N=59, 80, 58, 61]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.60" spread="122.291"/>
                    <measurement group_id="O2" value="116.46" spread="114.475"/>
                    <measurement group_id="O3" value="101.04" spread="121.681"/>
                    <measurement group_id="O4" value="143.86" spread="114.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52-56 Weeks [N=42, 88, 75, 71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.91" spread="134.943"/>
                    <measurement group_id="O2" value="110.59" spread="113.658"/>
                    <measurement group_id="O3" value="121.34" spread="129.149"/>
                    <measurement group_id="O4" value="167.72" spread="118.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72-76 Weeks [N=0, 77, 68, 60]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants remained in this treatment group.</measurement>
                    <measurement group_id="O2" value="125.21" spread="134.963"/>
                    <measurement group_id="O3" value="137.91" spread="136.870"/>
                    <measurement group_id="O4" value="200.67" spread="137.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>92-96 Weeks [N=0, 66, 56, 57]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants remained in this treatment group.</measurement>
                    <measurement group_id="O2" value="134.14" spread="172.834"/>
                    <measurement group_id="O3" value="163.31" spread="124.169"/>
                    <measurement group_id="O4" value="185.74" spread="118.865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Sleep Time</title>
        <description>Participants completed a sleep diary on 3 consecutive mornings prior to each study visit, from which the total sleep time was calculated and averaged for the 3 days. Baseline refers to Baseline of Study CS29 and the number of weeks represents the total exposure to study drug.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
        <time_frame>Baseline of Study CS29 and Weeks 8, 12, 20, 28, 52-56, 72-76, and 92-96.</time_frame>
        <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants received desmopressin Melt 10 μg once a day, placed under the tongue 1 hour before bedtime until they were re-randomized to 1 of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants received desmopressin Melt 25 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants received desmopressin Melt 50 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants received desmopressin Melt 100 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Sleep Time</title>
          <description>Participants completed a sleep diary on 3 consecutive mornings prior to each study visit, from which the total sleep time was calculated and averaged for the 3 days. Baseline refers to Baseline of Study CS29 and the number of weeks represents the total exposure to study drug.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
          <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8 Weeks [N=103, 96, 91, 104]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.93" spread="65.628"/>
                    <measurement group_id="O2" value="19.77" spread="71.609"/>
                    <measurement group_id="O3" value="33.17" spread="77.892"/>
                    <measurement group_id="O4" value="14.68" spread="76.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks [N=85, 81, 77, 81]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.66" spread="65.419"/>
                    <measurement group_id="O2" value="24.94" spread="65.785"/>
                    <measurement group_id="O3" value="30.34" spread="68.221"/>
                    <measurement group_id="O4" value="12.90" spread="73.777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 Weeks [N=61, 58, 64, 64]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.64" spread="63.952"/>
                    <measurement group_id="O2" value="36.13" spread="67.708"/>
                    <measurement group_id="O3" value="34.01" spread="93.074"/>
                    <measurement group_id="O4" value="24.54" spread="75.385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 Weeks [N=64, 85, 62, 62]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.12" spread="62.382"/>
                    <measurement group_id="O2" value="34.99" spread="65.342"/>
                    <measurement group_id="O3" value="33.99" spread="74.539"/>
                    <measurement group_id="O4" value="22.25" spread="69.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52-56 Weeks [N=46, 91, 80, 77]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.09" spread="65.705"/>
                    <measurement group_id="O2" value="20.86" spread="71.695"/>
                    <measurement group_id="O3" value="25.68" spread="95.625"/>
                    <measurement group_id="O4" value="15.84" spread="77.880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72-76 Weeks [N=0, 80, 72, 66]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants remained in this treatment group.</measurement>
                    <measurement group_id="O2" value="26.44" spread="70.467"/>
                    <measurement group_id="O3" value="33.22" spread="78.286"/>
                    <measurement group_id="O4" value="19.34" spread="92.171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>92-96 Weeks [N=0, 67, 61, 62]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants remained in this treatment group.</measurement>
                    <measurement group_id="O2" value="23.45" spread="65.624"/>
                    <measurement group_id="O3" value="37.33" spread="82.320"/>
                    <measurement group_id="O4" value="26.83" spread="95.183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in International Consultation on Incontinence Modular Questionnaire - Nocturia (ICIQ-N) Nighttime Urination Bother Score</title>
        <description>The ICIQ-N is a self-administered 4-item questionnaire designed to assess the frequency and bother of daytime and nighttime urination. To assess nighttime urination bother, participants were asked to rate the degree of bother of nighttime urination by answering the question “Night time urination: How much does this bother you?” on a scale ranging from 0 (not at all) to 10 (a great deal). Higher numbers indicate greater bother.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
        <time_frame>Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)</time_frame>
        <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants received desmopressin Melt 10 μg once a day, placed under the tongue 1 hour before bedtime until they were re-randomized to 1 of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants received desmopressin Melt 25 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants received desmopressin Melt 50 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants received desmopressin Melt 100 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in International Consultation on Incontinence Modular Questionnaire - Nocturia (ICIQ-N) Nighttime Urination Bother Score</title>
          <description>The ICIQ-N is a self-administered 4-item questionnaire designed to assess the frequency and bother of daytime and nighttime urination. To assess nighttime urination bother, participants were asked to rate the degree of bother of nighttime urination by answering the question “Night time urination: How much does this bother you?” on a scale ranging from 0 (not at all) to 10 (a great deal). Higher numbers indicate greater bother.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
          <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16 [N=34, 42, 44, 35]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.68" spread="3.409"/>
                    <measurement group_id="O2" value="-2.62" spread="3.695"/>
                    <measurement group_id="O3" value="-3.77" spread="3.436"/>
                    <measurement group_id="O4" value="-3.71" spread="3.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 12 [N=0, 84, 77, 67]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants remained in this treatment group.</measurement>
                    <measurement group_id="O2" value="-2.83" spread="3.488"/>
                    <measurement group_id="O3" value="-3.77" spread="3.211"/>
                    <measurement group_id="O4" value="-4.12" spread="3.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study [N=17, 93, 84, 82]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.12" spread="2.934"/>
                    <measurement group_id="O2" value="-2.96" spread="3.668"/>
                    <measurement group_id="O3" value="-3.46" spread="3.504"/>
                    <measurement group_id="O4" value="-3.62" spread="3.512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nocturia Quality of Life (NQoL) Overall Score</title>
        <description>The NQoL is a self-administered 13-item questionnaire designed to assess the impact of nocturia on quality of life. It contains a sleep/energy domain (6 questions), a bother/concern domain (6 questions), and 1 global QoL question (which is not included in the overall score). The 12 core items are scored on a 0 to 4 scale, and the overall score is calculated by transforming the raw score into a 0-100 scale with higher numbers indicating better impact on quality of life.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
        <time_frame>Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)</time_frame>
        <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants received desmopressin Melt 10 μg once a day, placed under the tongue 1 hour before bedtime until they were re-randomized to 1 of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants received desmopressin Melt 25 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants received desmopressin Melt 50 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants received desmopressin Melt 100 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nocturia Quality of Life (NQoL) Overall Score</title>
          <description>The NQoL is a self-administered 13-item questionnaire designed to assess the impact of nocturia on quality of life. It contains a sleep/energy domain (6 questions), a bother/concern domain (6 questions), and 1 global QoL question (which is not included in the overall score). The 12 core items are scored on a 0 to 4 scale, and the overall score is calculated by transforming the raw score into a 0-100 scale with higher numbers indicating better impact on quality of life.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
          <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16 [N=34, 42, 44, 35]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.16" spread="29.515"/>
                    <measurement group_id="O2" value="22.42" spread="18.752"/>
                    <measurement group_id="O3" value="22.06" spread="21.985"/>
                    <measurement group_id="O4" value="26.13" spread="22.728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 12 [N=0, 84, 77, 66]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants remained in this treatment group.</measurement>
                    <measurement group_id="O2" value="19.37" spread="19.362"/>
                    <measurement group_id="O3" value="21.51" spread="22.838"/>
                    <measurement group_id="O4" value="19.89" spread="19.684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study [N=17, 94, 85, 80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.87" spread="16.913"/>
                    <measurement group_id="O2" value="17.46" spread="20.497"/>
                    <measurement group_id="O3" value="19.13" spread="23.393"/>
                    <measurement group_id="O4" value="18.36" spread="19.684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in NQoL Bother/Concern Domain Score</title>
        <description>The NQoL is a self-administered 13-item questionnaire designed to assess the impact of nocturia on quality of life. It contains a sleep/energy domain (6 questions), a bother/concern domain (6 questions), and 1 global QoL question. The 12 core items are scored on a 0 to 4 scale with higher numbers indicating a better quality of life. The bother/concern domain summary score is calculated by transforming the raw score into a 0-100 scale with higher numbers indicating a better impact on quality of life.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
        <time_frame>Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)</time_frame>
        <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants received desmopressin Melt 10 μg once a day, placed under the tongue 1 hour before bedtime until they were re-randomized to 1 of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants received desmopressin Melt 25 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants received desmopressin Melt 50 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants received desmopressin Melt 100 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in NQoL Bother/Concern Domain Score</title>
          <description>The NQoL is a self-administered 13-item questionnaire designed to assess the impact of nocturia on quality of life. It contains a sleep/energy domain (6 questions), a bother/concern domain (6 questions), and 1 global QoL question. The 12 core items are scored on a 0 to 4 scale with higher numbers indicating a better quality of life. The bother/concern domain summary score is calculated by transforming the raw score into a 0-100 scale with higher numbers indicating a better impact on quality of life.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
          <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16 [N=34, 42, 44, 35]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.43" spread="28.977"/>
                    <measurement group_id="O2" value="22.82" spread="20.083"/>
                    <measurement group_id="O3" value="23.30" spread="26.783"/>
                    <measurement group_id="O4" value="28.81" spread="27.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 12 [N=0, 83, 77, 66]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants remained in this treatment group.</measurement>
                    <measurement group_id="O2" value="18.27" spread="21.979"/>
                    <measurement group_id="O3" value="19.70" spread="23.702"/>
                    <measurement group_id="O4" value="17.11" spread="21.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study [N=17, 94, 84, 80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.73" spread="23.047"/>
                    <measurement group_id="O2" value="14.23" spread="20.589"/>
                    <measurement group_id="O3" value="16.47" spread="25.871"/>
                    <measurement group_id="O4" value="16.25" spread="21.335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nocturia Quality of Life (NQoL) Sleep/Energy Domain Score</title>
        <description>The NQoL is a self-administered 13-item questionnaire designed to assess the impact of nocturia on quality of life. It contains a sleep/energy domain (6 questions), a bother/concern domain (6 questions), and 1 global QoL question. The 12 core items are scored on a 0 to 4 scale with higher numbers indicating a better quality of life. The sleep/energy domain summary score is calculated by transforming the raw score into a 0-100 scale with higher numbers indicating a better impact on quality of life.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
        <time_frame>Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)</time_frame>
        <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants received desmopressin Melt 10 μg once a day, placed under the tongue 1 hour before bedtime until they were re-randomized to 1 of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants received desmopressin Melt 25 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants received desmopressin Melt 50 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants received desmopressin Melt 100 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nocturia Quality of Life (NQoL) Sleep/Energy Domain Score</title>
          <description>The NQoL is a self-administered 13-item questionnaire designed to assess the impact of nocturia on quality of life. It contains a sleep/energy domain (6 questions), a bother/concern domain (6 questions), and 1 global QoL question. The 12 core items are scored on a 0 to 4 scale with higher numbers indicating a better quality of life. The sleep/energy domain summary score is calculated by transforming the raw score into a 0-100 scale with higher numbers indicating a better impact on quality of life.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
          <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16 [N=34, 42, 44, 35]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.89" spread="34.152"/>
                    <measurement group_id="O2" value="22.02" spread="20.645"/>
                    <measurement group_id="O3" value="20.83" spread="20.333"/>
                    <measurement group_id="O4" value="23.45" spread="21.534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 12 [N=0, 85, 77, 66]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants remained in this treatment group.</measurement>
                    <measurement group_id="O2" value="20.20" spread="21.046"/>
                    <measurement group_id="O3" value="23.32" spread="25.311"/>
                    <measurement group_id="O4" value="22.66" spread="20.829"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study [N=17, 93, 84, 81]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.01" spread="18.510"/>
                    <measurement group_id="O2" value="20.30" spread="25.070"/>
                    <measurement group_id="O3" value="21.83" spread="23.884"/>
                    <measurement group_id="O4" value="20.58" spread="22.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Nocturia Quality of Life (NQoL) Global Quality of Life Score</title>
        <description>The NQoL is a self-administered 13-item questionnaire designed to assess the impact of nocturia on quality of life. It contains a sleep/energy domain (6 questions), a bother/concern domain (6 questions), and 1 global QoL question. The global QoL question is scored on a scale ranging from 0 (not at all) to 10 (a great deal). Higher numbers indicate better impact on quality of life.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
        <time_frame>Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)</time_frame>
        <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants received desmopressin Melt 10 μg once a day, placed under the tongue 1 hour before bedtime until they were re-randomized to 1 of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants received desmopressin Melt 25 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants received desmopressin Melt 50 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants received desmopressin Melt 100 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Nocturia Quality of Life (NQoL) Global Quality of Life Score</title>
          <description>The NQoL is a self-administered 13-item questionnaire designed to assess the impact of nocturia on quality of life. It contains a sleep/energy domain (6 questions), a bother/concern domain (6 questions), and 1 global QoL question. The global QoL question is scored on a scale ranging from 0 (not at all) to 10 (a great deal). Higher numbers indicate better impact on quality of life.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
          <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16 [N=34, 42, 44, 35]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.799"/>
                    <measurement group_id="O2" value="0.36" spread="0.932"/>
                    <measurement group_id="O3" value="0.68" spread="0.708"/>
                    <measurement group_id="O4" value="0.26" spread="0.701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 12 [N=0, 85, 77, 69]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants remained in this treatment group.</measurement>
                    <measurement group_id="O2" value="0.38" spread="1.112"/>
                    <measurement group_id="O3" value="0.48" spread="0.788"/>
                    <measurement group_id="O4" value="0.46" spread="0.867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study [N=17, 93, 85, 81]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.529"/>
                    <measurement group_id="O2" value="0.34" spread="0.801"/>
                    <measurement group_id="O3" value="0.47" spread="0.933"/>
                    <measurement group_id="O4" value="0.43" spread="0.851"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Global Score</title>
        <description>The PSQI is a self-administered 19-item questionnaire designed to assess sleep quality and disturbances. The 19 individual items are scored on an evenly weighted 0 to 3 scale and generate 7 component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these 7 components yields 1 global score ranging from 0 to 21. Higher numbers indicate greater sleep disturbance.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
        <time_frame>Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)</time_frame>
        <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants received desmopressin Melt 10 μg once a day, placed under the tongue 1 hour before bedtime until they were re-randomized to 1 of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants received desmopressin Melt 25 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants received desmopressin Melt 50 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants received desmopressin Melt 100 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Global Score</title>
          <description>The PSQI is a self-administered 19-item questionnaire designed to assess sleep quality and disturbances. The 19 individual items are scored on an evenly weighted 0 to 3 scale and generate 7 component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these 7 components yields 1 global score ranging from 0 to 21. Higher numbers indicate greater sleep disturbance.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
          <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16 [N=32, 39, 42, 34]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.41" spread="3.555"/>
                    <measurement group_id="O2" value="-2.59" spread="3.507"/>
                    <measurement group_id="O3" value="-3.52" spread="3.556"/>
                    <measurement group_id="O4" value="-2.94" spread="3.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 12 [N=0, 80, 73, 65]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants remained in this treatment group.</measurement>
                    <measurement group_id="O2" value="-1.59" spread="3.546"/>
                    <measurement group_id="O3" value="-2.99" spread="3.747"/>
                    <measurement group_id="O4" value="-2.66" spread="3.374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study [N=16, 89, 78, 78]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.69" spread="2.387"/>
                    <measurement group_id="O2" value="-2.12" spread="3.680"/>
                    <measurement group_id="O3" value="-2.88" spread="4.212"/>
                    <measurement group_id="O4" value="-1.54" spread="3.617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Short Form-12, Version 2 (SF-12v2) Mental Component Summary Score</title>
        <description>The SF-12v2 was used to measure the impact of nocturia and lack of sleep on general quality of life. The SF-12 consists of 12 questions spanning 8 domains: physical functioning, role function-physical, role function-emotional, bodily pain, general health, vitality, social functioning, and mental health. These scales are combined to create 2 summary measures: the Physical Health Summary and Mental Health Summary. The Mental Health Summary score ranges from 0 to 100, where higher numbers indicate better quality of life.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
        <time_frame>Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)</time_frame>
        <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants received desmopressin Melt 10 μg once a day, placed under the tongue 1 hour before bedtime until they were re-randomized to 1 of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants received desmopressin Melt 25 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants received desmopressin Melt 50 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants received desmopressin Melt 100 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Short Form-12, Version 2 (SF-12v2) Mental Component Summary Score</title>
          <description>The SF-12v2 was used to measure the impact of nocturia and lack of sleep on general quality of life. The SF-12 consists of 12 questions spanning 8 domains: physical functioning, role function-physical, role function-emotional, bodily pain, general health, vitality, social functioning, and mental health. These scales are combined to create 2 summary measures: the Physical Health Summary and Mental Health Summary. The Mental Health Summary score ranges from 0 to 100, where higher numbers indicate better quality of life.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
          <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16 [N=34, 42, 44, 34]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.82" spread="7.784"/>
                    <measurement group_id="O2" value="3.84" spread="9.101"/>
                    <measurement group_id="O3" value="1.57" spread="8.910"/>
                    <measurement group_id="O4" value="4.14" spread="8.590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 12 [N=0, 82, 73, 66]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants remained in this treatment group.</measurement>
                    <measurement group_id="O2" value="0.53" spread="8.167"/>
                    <measurement group_id="O3" value="1.39" spread="11.163"/>
                    <measurement group_id="O4" value="0.14" spread="8.858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study [N=17, 91, 81, 80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="8.426"/>
                    <measurement group_id="O2" value="3.15" spread="9.929"/>
                    <measurement group_id="O3" value="1.77" spread="12.017"/>
                    <measurement group_id="O4" value="1.30" spread="9.954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Short Form-12, Version 2 (SF-12v2) Physical Component Summary Score</title>
        <description>The SF-12v2 was used to measure the impact of nocturia and lack of sleep on general quality of life. The SF-12 consists of 12 questions spanning 8 domains: physical functioning, role function-physical, role function-emotional, bodily pain, general health, vitality, social functioning, and mental health. These scales are combined to create 2 summary measures: the Physical Health Summary and Mental Health Summary. The Physical Health Summary score ranges from 0 to 100, where higher numbers indicate better quality of life.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
        <time_frame>Baseline of Study CS29, Week 16, Visit 12 (approximately 56-78 weeks total study time) and End of Study (up to a maximum of 35 months)</time_frame>
        <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants received desmopressin Melt 10 μg once a day, placed under the tongue 1 hour before bedtime until they were re-randomized to 1 of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants received desmopressin Melt 25 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants received desmopressin Melt 50 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants received desmopressin Melt 100 μg once a day, placed under the tongue 1 hour before bedtime for up to 2 years and 2.5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Short Form-12, Version 2 (SF-12v2) Physical Component Summary Score</title>
          <description>The SF-12v2 was used to measure the impact of nocturia and lack of sleep on general quality of life. The SF-12 consists of 12 questions spanning 8 domains: physical functioning, role function-physical, role function-emotional, bodily pain, general health, vitality, social functioning, and mental health. These scales are combined to create 2 summary measures: the Physical Health Summary and Mental Health Summary. The Physical Health Summary score ranges from 0 to 100, where higher numbers indicate better quality of life.
Participants in the 10μg arm are included only until the time of dose escalation.</description>
          <population>Efficacy Analysis dataset = CS29 ITT population (all randomized patients who received &gt;=1 dose of study drug and provided &gt;=1 primary efficacy measure during Part I) who were on active treatment. # analyzed represents baseline participants. N= indicates # of participants for whom data were also available at the post-baseline time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16 [N=34, 42, 44, 34]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="7.387"/>
                    <measurement group_id="O2" value="1.42" spread="7.444"/>
                    <measurement group_id="O3" value="2.62" spread="6.934"/>
                    <measurement group_id="O4" value="0.14" spread="8.900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 12 [N=0, 82, 73, 66]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants remained in this treatment group.</measurement>
                    <measurement group_id="O2" value="1.35" spread="8.170"/>
                    <measurement group_id="O3" value="2.08" spread="8.879"/>
                    <measurement group_id="O4" value="2.28" spread="7.222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study [N=17, 91, 81, 80]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="4.077"/>
                    <measurement group_id="O2" value="-0.02" spread="7.274"/>
                    <measurement group_id="O3" value="1.75" spread="8.794"/>
                    <measurement group_id="O4" value="-0.67" spread="9.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Treatment-Emergent Adverse Events (AEs)</title>
        <description>An AE was any untoward medical occurrence that did not necessarily have a causal relationship with the study drug. An adverse drug reaction (ADR) was an AE evaluated by the Investigator as being probably or possibly causally related to treatment with the study drug.
A serious AE (SAE) was any event that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or congenital anomaly/birth defect or was an important medical event that could have jeopardized the patient's safety or required medical or surgical intervention to prevent 1 of the outcomes listed above. The intensity of an AE was defined as severe if it resulted in the inability to work or perform usual activities.</description>
        <time_frame>From first dose of study drug in Study CS29 until the end of study CS31 (up to 35 months).</time_frame>
        <population>Safety dataset included all patients who received at least 1 dose of study drug in either Study CS29 or CS31 and counted patients according to their study drug exposure; therefore patients could be included in more than 1 treatment arm. Of the 1023 patients, 799 were unique patients enrolled in CS29, 222 were re-randomized and 2 had dose decreased.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants took a placebo 'Melt' for 28 days to complete Part I of study CS29. In Part II, placebo patients were randomized to 1 of the other 4 treatment arms to receive active desmopressin Melt.</description>
          </group>
          <group group_id="O2">
            <title>Desmopressin Melt 10 μg</title>
            <description>Participants received desmopressin Melt 10 μg once a day, in CS29 and CS31 until they were re-randomized to 1 of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).</description>
          </group>
          <group group_id="O3">
            <title>Desmopressin Melt 25 μg</title>
            <description>Participants received desmopressin Melt 25 μg once a day, in CS29 or CS31. This group includes participants initially randomized to placebo and re-randomized at the end of CS29 Part I and participants initially receiving 10 μg re-randomized during CS31.</description>
          </group>
          <group group_id="O4">
            <title>Desmopressin Melt 50 μg</title>
            <description>Participants received desmopressin Melt 50 μg once a day, in CS29 or CS31. This group includes participants initially randomized to placebo and re-randomized at the end of CS29 Part I and participants initially receiving 10 μg re-randomized during CS31.</description>
          </group>
          <group group_id="O5">
            <title>Desmopressin Melt 100 μg</title>
            <description>Participants received desmopressin Melt 100 μg once a day, in CS29 or CS31. This group includes participants initially randomized to placebo and re-randomized at the end of CS29 Part I and participants initially receiving 10 μg re-randomized during CS31.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Treatment-Emergent Adverse Events (AEs)</title>
          <description>An AE was any untoward medical occurrence that did not necessarily have a causal relationship with the study drug. An adverse drug reaction (ADR) was an AE evaluated by the Investigator as being probably or possibly causally related to treatment with the study drug.
A serious AE (SAE) was any event that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or congenital anomaly/birth defect or was an important medical event that could have jeopardized the patient's safety or required medical or surgical intervention to prevent 1 of the outcomes listed above. The intensity of an AE was defined as severe if it resulted in the inability to work or perform usual activities.</description>
          <population>Safety dataset included all patients who received at least 1 dose of study drug in either Study CS29 or CS31 and counted patients according to their study drug exposure; therefore patients could be included in more than 1 treatment arm. Of the 1023 patients, 799 were unique patients enrolled in CS29, 222 were re-randomized and 2 had dose decreased.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="195"/>
                <count group_id="O3" value="227"/>
                <count group_id="O4" value="217"/>
                <count group_id="O5" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="149"/>
                    <measurement group_id="O3" value="188"/>
                    <measurement group_id="O4" value="187"/>
                    <measurement group_id="O5" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse drug reactions (ADRs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="87"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug in Study CS29 until the end of Study CS31 (up to 35 months).</time_frame>
      <desc>Safety dataset included all patients who received at least 1 dose of study drug in either Study CS29 or CS31 and counted patients according to their study drug exposure, therefore patients could be included in more than 1 treatment arm. Of the 1023 patients, 799 were unique patients enrolled in CS29, 222 were re-randomized and 2 had dose decreased.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants took a placebo 'melt' for 28 days to complete Part I of study CS29. In Part II, placebo patients were randomized to one of the other four treatment arms to receive active desmopressin melt.</description>
        </group>
        <group group_id="E2">
          <title>Desmopressin Melt 10 μg</title>
          <description>Participants received desmopressin melt 10 μg once a day, in CS29 and CS31 until they were re-randomized to one of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).</description>
        </group>
        <group group_id="E3">
          <title>Desmopressin Melt 25 μg</title>
          <description>Participants received desmopressin melt 25 μg once a day, in CS29 or CS31. This group includes participants initially randomized to placebo and re-randomized at the end of CS29 Part I and participants initially receiving 10 μg re-randomized during CS31.</description>
        </group>
        <group group_id="E4">
          <title>Desmopressin Melt 50 μg</title>
          <description>Participants received desmopressin melt 50 μg once a day, in CS29 or CS31. This group includes participants initially randomized to placebo and re-randomized at the end of CS29 Part I and participants initially receiving 10 μg re-randomized during CS31.</description>
        </group>
        <group group_id="E5">
          <title>Desmopressin Melt 100 μg</title>
          <description>Participants received desmopressin melt 100 μg once a day, in CS29 or CS31. This group includes participants initially randomized to placebo and re-randomized at the end of CS29 Part I and participants initially receiving 10 μg re-randomized during CS31.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Thrombocythaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Left Ventricular Hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Abdominal Adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pelvic Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Clavicle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Scapula Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Shunt Malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Splenic Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Lumbar Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Spinal Column Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <description>Gender-specific to males; denominator is based on the male population</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Adenosquamous Cell Lung Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Bladder Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Breast Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Lung Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Rectal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Ureteric Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Subarachnoid Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Coordination Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Loss Of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Radiculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <description>Gender-specific to males; denominator is based on the male population</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Haemopneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee Arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm Ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Aortic Aneurysm Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Femoral Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="147" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="154" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="146" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="61" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="227"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="217"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

